TGFB1 and gastric cancer: This implies that TGF-β signaling activity may serve as a potential intervention point to overcome ICI resistance, but whether targeting TGF-β to overcome ICI resistance will be successful in GC patients is uncertain and needs to be verified by relevant clinical trials.